Pharmafile Logo

LMTX

- PMLiVE

Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures

Earnings were particularly impacted by lower demand for top diabetes drug Trulicity

- PMLiVE

Eli Lilly ends COVID-19 antibody trial in hospitalised setting, other studies continue

Bamlanivimab is being studied in a number of additional ongoing trials

- PMLiVE

Independent consultant will review Lilly’s COVID-19 plant issues

COVID-19 antibody trial was paused last week due to safety issue

- PMLiVE

Lilly buys biotech firm Disarm Therapeutics for $135m

Deal could eventually be worth up to $1.36bn

- PMLiVE

Eli Lilly’s COVID-19 antibody trial paused due to safety issue

Company has voluntarily paused study amid safety review

- PMLiVE

Lilly seeks US emergency approval after posting new data for COVID-19 antibodies

Combination of two antibodies reduced viral load and symptoms of COVID-19

- PMLiVE

AbbVie’s HIV therapy Kaletra fails to show efficacy in COVID-19

Drug failed to improved condition of hospitalised COVID-19 patients

- PMLiVE

FDA sets November date for expert panel review of Biogen’s aducanumab

Advisory committee will review biologics license application for controversial therapy

- PMLiVE

Lilly’s Verzenio scores a win in early-stage breast cancer

Positive data was presented at 2020 ESMO virtual congress

- PMLiVE

Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19

The combination treatment hit the primary study endpoint of a reduction in recovery time

- PMLiVE

AbbVie signs immunotherapy pact with I-Mab worth $2bn

Focus of deal is anti-CD47 monoclonal antibody lemzoparlimab

- PMLiVE

AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML

Data from the trial has been published in the New England Journal of Medicine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links